Efficacy And Safety Of Ashwagandha Root Extract In Subclinical Hypothyroid Patients: A Double-Blind, Randomized Placebo-Controlled Trial
Notes for this study:
||(uIU/mL). Placebo: before 6.72 (0.93, after 7.05 (1.93). Ashwagandha: before 6.48 (0.85), after 5.35 (1.08)
|Number of Subjects
||18-29, 30-44, 45-64
In a randomized, double-blind, placebo-controlled trial, 50 participants with subclinical hypothyroidism were assigned to take 600 mg of a 100% aqueous extract of ashwagandha (5% withanolides) or placebo daily for 8 weeks.
There was a notable, statistically significant increase in T3 and T4 and a notable reduction in TGH in the ashwagandha group compared with the placebo group.
There was no notable difference between groups for adverse events.